This study is in progress, not accepting new patients
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Summary
- Eligibility
- for people ages 60-90 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- ID
- NCT04640077
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 90 people participating
- Last Updated